Janssen Biotech, Inc.

Quick facts

Phase 2 pipeline

• anti-TNF biologics
• Anti TNF therapy including infliximab · Immunology
  Blocks tumor necrosis factor-alpha (TNF-alpha) by binding to it and preventing it from interacting with cell surface TNF receptors.
• No Biologics
• non-anti-TNF biologics
• systemic non-biological treatments

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Janssen Biotech, Inc. portfolio CI brief
• Janssen Biotech, Inc. pipeline updates RSS